Prevention and treatment of relapse after stem cell transplantation by cellular therapies (Q88797021)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29795426 AND SRC:MED&resulttype=core&format=json

27 March 2020

title

Prevention and treatment of relapse after stem cell transplantation by cellular therapies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29795426 AND SRC:MED&resulttype=core&format=json

27 March 2020

author name string

Fred Falkenburg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29795426 AND SRC:MED&resulttype=core&format=json

27 March 2020

Eliana Ruggiero

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29795426 AND SRC:MED&resulttype=core&format=json

27 March 2020

Jeff Miller

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29795426 AND SRC:MED&resulttype=core&format=json

27 March 2020

Floran Malard

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29795426 AND SRC:MED&resulttype=core&format=json

27 March 2020

Mohamad Mohty

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29795426 AND SRC:MED&resulttype=core&format=json

27 March 2020

Nicolaus Kröger

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29795426 AND SRC:MED&resulttype=core&format=json

27 March 2020

Hans Jochem Kolb

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29795426 AND SRC:MED&resulttype=core&format=json

27 March 2020

publication date

24 May 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29795426 AND SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

27 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29795426 AND SRC:MED&resulttype=core&format=json

27 March 2020

volume

54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29795426 AND SRC:MED&resulttype=core&format=json

27 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29795426 AND SRC:MED&resulttype=core&format=json

27 March 2020

page(s)

26-34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29795426 AND SRC:MED&resulttype=core&format=json

Allo-reactive T cells for the treatment of hematological malignancies

27 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Positive and negative selection of T cells

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

The human leukocyte antigen-presented ligandome of B lymphocytes

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Finding the sweet spot for donor lymphocyte infusions

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future.

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Langerhans cell homeostasis and turnover after nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cells

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Breakthrough of the year 2013. Cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Cancer regression in patients after transfer of genetically engineered lymphocytes

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Targeting human melanoma neoantigens by T cell receptor gene therapy

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Safety of retroviral gene marking with a truncated NGF receptor

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory.

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Chimeric antigen receptor T cells for sustained remissions in leukemia

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

CD19 CAR-T cells of defined CD4 :CD8 composition in adult B cell ALL patients

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8 and CD4 CD19-specific chimeric antigen receptor-modified T cells

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Mixed T cell receptor dimers harbor potentially harmful neoreactivity

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease.

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

T cell exclusion, immune privilege, and the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

https://api.crossref.org/works/10.1038/S41409-018-0227-0

1 reference

7 January 2021

Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Generation of knock-in primary human T cells using Cas9 ribonucleoproteins.

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

T memory stem cells in health and disease.

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyond

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Toxicities of chimeric antigen receptor T cells: recognition and management

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15.

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Interleukin-21 differentially affects human natural killer cell subsets

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Phase 1 clinical trial using mbIL21 ex-vivo expanded donor-derived NK cells after haploidentical transplantation

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

CD56dimCD57 NKG2C NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT.

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

GSK 3 inhibition drives maturation of NK cells and enhances their antitumor activity

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33 targets

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33 Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Are natural killer cells superior CAR drivers?

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Advantages and applications of CAR-expressing natural killer cells

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective s

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de Moelle (SFGM)

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant.

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes.

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

Modern approaches to HLA-haploidentical blood or marrow transplantation

1 reference

https://api.crossref.org/works/10.1038/S41409-018-0227-0

7 January 2021

10.1038/S41409-018-0227-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29795426 AND SRC:MED&resulttype=core&format=json

27 March 2020

1 reference